FLUORES ® Fluconazole

FLUORES ® is a Fluconazole based drug

THERAPEUTIC GROUP: Antimycotics for systemic use - triazole derivatives

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications FLUORES ® Fluconazole

FLUORES ® is indicated in the treatment of deep fungal infections sustained by dermatophytes, yeasts and fungi sensitive to antifungals such as Fluconazole.

This drug can also be used during superficial fungal infections if topical therapy is ineffective.

The action of Fluconazole has also proved important in the prevention of secondary fungal infections in immunosuppressed patients.

Mechanism of action FLUORES ® Fluconazole

FLUORES ® is a drug based on Fluconazole, an antifungal drug with a broad spectrum of action, particularly useful in the treatment of deep fungal infections and in the prevention of fungal infections secondary to conditions of immunodepression.

The high therapeutic activity is guaranteed both by the excellent bioavailability of the drug and by the advantageous pharmacokinetic profile, which ensures a uniform distribution of the active ingredient among the various tissues.

After reaching the pathogenic cell, Fluconazole easily permeates the plasma membrane concentrating in the cytosol and inhibiting enzymes involved in the synthesis of ergosterol, a key element of cell structure and functionality.

The aforementioned inhibitory activity also determines the accumulation of intermediate catabolites, which by interacting with membrane enzymes involved in the various metabolic processes, block the different energy and biosynthetic pathways compromising cellular functionality.

All this translates into a clinically relevant cytostatic and antifungal activity.

Studies carried out and clinical efficacy

THE USE OF THE FLUCONAZOLE IN THE RESUSCITATION DEPARTMENTS

Infect Drug Resist. 2013; 6: 15-25.

Clinical trial showing that about one-third of patients admitted to intensive care units can develop fungal Candida infections, generally resistant to common Fluconazole therapy.

FLUCONAZOLE AND CIPROFLOXACINE IN PRETERMINE NEWBORNS

BMC Pediatr. 2013 Jan 7; 13: 5.

Interesting Italian study that demonstrates the need to identify prophylactic protocols that are effective in reducing the incidence of fungal infections in preterm infants. In this sense the use of Ciprofloxacin and Fluconazole could be particularly effective.

SURGERY + FLUCONAZOLE IN THE TREATMENT OF FUNGIN RHINOSINUSITIS

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Aug; 26 (15): 692-3, 696.

Work that combines the use of Fluconazole with surgery in the treatment of fungal rhinosinusitis, thus ensuring both an improvement in therapy and greater protection from possible relapses.

Method of use and dosage

FLUORES ®

Hard capsules of 100 mg - 150 mg and 200 mg of Fluconazole.

The complexity of the therapy and the need to fine-tune the dosages according to the patient's clinical needs require specialized medical supervision both in the initial phases of the treatment and during the entire therapeutic process.

Warnings FLUORES ® Fluconazole

The potential side effects of Fluconazole, which could cause significant damage to the liver, kidney and heart in predisposed patients, considerably limit the use of FLUORES ® in patients with liver disease, nephropathy and heart disease.

For this reason, before starting therapy with FLUORES ® it would be advisable for the doctor to carefully assess the patient's overall health status considering all the possible contraindications to the use of the drug and to any situations that require an adjustment of the therapy in progress.

The presence of lactose among the excipients of FLUORES ® could lead to the appearance of even serious side effects in patients with lactase enzyme deficiency, glucose-galactose malabsorption syndrome and lactose intolerance.

PREGNANCY AND BREASTFEEDING

The use of Fluconazole is generally contraindicated during pregnancy and in the subsequent period of breastfeeding, given the absence of studies able to fully characterize the safety profile of the drug for the health of the fetus and infant.

Interactions

The ability of Fluconazole to inhibit the activity of liver enzymes such as cytochromes CYP3A4 and CYP2C9 involved in the metabolism of numerous active ingredients exposes the patient on FLUORES ® therapy to the risk of numerous pharmacologically relevant interactions.

More precisely, the simultaneous administration of drugs such as oral anticoagulants, azithromycin, benzodiazepines, cyclosporine, cyclophosphamide, statins, antihypertensives, oral contraceptives, phenytoin, prednisone, immunosuppressants and others, could determine the onset of serious side effects related to the variation of the pharmacokinetic properties of themselves induced by Fluconazole.

At the same time, the intake of antacid drugs could reduce the systemic absorption of the drug, compromising its therapeutic efficacy.

Contraindications FLUORES ® Fluconazole

The use of FLUORES ® is contraindicated in patients hypersensitive to the active ingredient or to one of its excipients, rather than in patients contextually subjected to pharmacological therapies with active principles metabolised by the cytochromial system.

Undesirable effects - Side effects

The use of FLUORES ®, especially when prolonged for a long time, could cause the onset of headache, abdominal pain, diarrhea, nausea, vomiting, hypertransaminasemia, skin rash and dermatological reactions from hypersensitivity to the product.